Polyrizon (PLRZ) Competitors $1.12 +0.11 (+10.89%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. JATT, RNTX, CVKD, BDRX, DYAI, TENX, FBLG, CASI, NNVC, and NAIIShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include JATT Acquisition (JATT), Rein Therapeutics (RNTX), Cadrenal Therapeutics (CVKD), Biodexa Pharmaceuticals (BDRX), Dyadic International (DYAI), Tenax Therapeutics (TENX), FibroBiologics (FBLG), CASI Pharmaceuticals (CASI), NanoViricides (NNVC), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Its Competitors JATT Acquisition Rein Therapeutics Cadrenal Therapeutics Biodexa Pharmaceuticals Dyadic International Tenax Therapeutics FibroBiologics CASI Pharmaceuticals NanoViricides Natural Alternatives International JATT Acquisition (NYSE:JATT) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Is JATT or PLRZ more profitable? Polyrizon's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Polyrizon N/A N/A N/A Do insiders and institutionals hold more shares of JATT or PLRZ? 48.0% of JATT Acquisition shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to JATT or PLRZ? In the previous week, Polyrizon had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for JATT Acquisition. Polyrizon's average media sentiment score of 0.96 beat JATT Acquisition's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Polyrizon Positive Which has higher earnings & valuation, JATT or PLRZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/APolyrizonN/AN/A-$1.54MN/AN/A SummaryJATT Acquisition beats Polyrizon on 4 of the 7 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.05M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / SalesN/A356.37470.61115.79Price / CashN/A43.0338.2159.48Price / Book0.008.608.866.15Net Income-$1.54M-$54.65M$3.25B$265.06M7 Day Performance1.82%5.86%3.72%2.60%1 Month Performance7.69%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.49%25.58% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.12+10.9%N/AN/A$6.05MN/A0.00N/ANews CoverageJATTJATT AcquisitionN/A$1.59+8.2%N/A-51.7%$27.43MN/A0.003Gap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.19-1.3%N/AN/A$27.31MN/A-0.419News CoverageEarnings ReportCVKDCadrenal Therapeutics2.9203 of 5 stars$12.62+8.0%$32.00+153.6%N/A$25.78MN/A-1.424Earnings ReportShort Interest ↑Analyst RevisionGap UpBDRXBiodexa Pharmaceuticals1.0231 of 5 stars$7.02+1.5%N/AN/A$25.63MN/A0.0020Positive NewsShort Interest ↓DYAIDyadic International3.3962 of 5 stars$0.83+1.2%$6.00+622.9%-40.3%$24.98M$3.49M-4.157Earnings ReportGap UpTENXTenax Therapeutics1.9868 of 5 stars$5.86-0.9%$17.50+198.9%+50.6%$24.36MN/A-2.379News CoverageEarnings ReportAnalyst ForecastFBLGFibroBiologics3.2231 of 5 stars$0.58-1.7%$13.00+2,145.3%-65.8%$24.09MN/A-1.6010Short Interest ↑Gap DownCASICASI Pharmaceuticals4.1757 of 5 stars$1.91+4.2%$4.00+109.9%-69.2%$23.58M$28.54M-0.75180Gap DownNNVCNanoViricides0.3107 of 5 stars$1.47-2.3%N/A-23.0%$23.55MN/A-2.0320NAIINatural Alternatives International1.5526 of 5 stars$3.78-1.2%N/A-27.6%$23.34M$113.80M-2.72290 Related Companies and Tools Related Companies JATT Acquisition Alternatives Rein Therapeutics Alternatives Cadrenal Therapeutics Alternatives Biodexa Pharmaceuticals Alternatives Dyadic International Alternatives Tenax Therapeutics Alternatives FibroBiologics Alternatives CASI Pharmaceuticals Alternatives NanoViricides Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access